Results from OVATION 2 Study continue to validate TheraPlas® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment IMNN-001 continues to show ...

New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...

CereVasc today announced the first patient randomized to and treated with the eShunt system in its STRIDE clinical trial.

Imunon (IMNN) announced new translational data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of IMNN-001, its ...

THIRUVANANTHAPURAM: In increase in the cost of treatment and medication has left kidney patients in the state facing a severe ...

In lieu of the World Kidney Day that falls on March 13, the National Institute Nephrology Dialysis and Transplantation ...

Nontraumatic lymphatic leaks in cancer patients are less understood and therefore more challenging to manage. Interventional ...

We look forward to advancing this program to a Phase 3 pivotal trial, which remains on track to start this quarter." In this analysis increases in IL-12 levels were sampled in the peritoneal fluid ...

CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced today that the first patient has been randomized to and treated with the ...

Beacon Journal sports writer George M. Thomas details the obstacles on his way to receiving a kidney transplant.

Celonic Group, a biologics CDMO, has signed a multi-year commercial manufacturing agreement with LINDIS Biotech for the ...

Free fluid in the peritoneal cavity should raise suspicion for a ruptured ectopic pregnancy with hemoperitoneum if no intrauterine pregnancy is seen on ultrasonography.